Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)


Blacks and Exacerbations on LABA vs. Tiotropium (BELT)




We are doing this study to learn how genes affect the way that people, specifically Black people, respond to treatment for asthma. Recent studies suggest that people respond differently to some asthma medications (eg Serevent, Foradil). Some people feel better when they use these inhalers, but others may not, and some people get worse. It seems that this difference shows up more often in Blacks than in Whites, which is why we are looking for Black subjects for this study. In all people, this difference seems to depend on their genes or DNA. This study is comparing the use of long acting asthma medications (Serevent, Foradil) to Tiotropium (Spiriva) for the treatment of asthma. Spiriva is used to treat chronic obstructive pulmonary disease (COPD). This study will help to see if this medication is also useful for treating asthma and whether it works better for some people than the current asthma medications.

Study Status: Completed


Condition Intervention Phase
Asthma Drug: Tiotropium
Drug: Salmeterol
Drug: Formoterol
Phase 3

Verified by Brigham and Women`s Hospital July, 2013

Sponsored by: Brigham and Women`s Hospital
Information provided by: Brigham and Women`s Hospital identifier: NCT01290874

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Elliot Israel, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site